ImmunityBio revenue and financials
$10.73Change from previous close: +4.28%Absolute change: +$0.44
In the fiscal year ended December 2025, ImmunityBio reported revenue of $113.29M (+668.31% year over year). The net loss was $351.4M.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +668.31%
- 2025 vs 2024
- Net margin
- -310.2%
- 2024: -2,804.8%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total revenue | 51.2 | 44.2 | 38.3 | 32.1 | 26.4 |
| Cost of revenue | 0.3 | 0.2 | 0.4 | 0.2 | 0.1 |
| Gross profit | 50.9 | 44.0 | 37.9 | 31.9 | 26.3 |
| Selling, general and administrative | 51.8 | 45.8 | 38.7 | 36.3 | 42.3 |
| Research and development | 60.8 | 68.0 | 63.9 | 51.2 | 55.2 |
| Operating income | -61.7 | -69.8 | -64.7 | -55.6 | -71.3 |
| EBIT | -199 | -604 | -34.9 | -39.7 | -63.4 |
| EBITDA | -195 | -600 | -31.0 | -35.8 | -59.5 |
| Interest expense | 31.2 | 28.5 | 27.2 | 27.6 | 28.9 |
| Pre-tax income | -230 | -633 | -62.1 | -67.3 | -92.3 |
| Income tax | 0.0 | 0.0 | -0.1 | -0.0 | 0.3 |
| Net income | -230 | -633 | -61.9 | -67.3 | -92.6 |
| Net income to common shareholders | -230 | -633 | -61.9 | -67.3 | -92.6 |
| Basic EPS | -0.22 | -0.62 | -0.06 | -0.07 | -0.10 |
| Diluted EPS | -0.22 | -0.62 | -0.06 | -0.07 | -0.10 |
| Average shares (basic) | 1,050 | 1,027 | 990 | 947 | 888 |
| Average shares (diluted) | 1,050 | 1,027 | 990 | 947 | 888 |